title: Development of Next-Generation Immunomodulatory Antibodies for Cancer Therapy through Optimization of the IgG Framework.
abstract: In this issue of Cancer Cell, Dahan and colleagues demonstrate that the Fc region has a significant impact on the therapeutic capacity of checkpoint inhibitor antibodies targeting the PD-1/PD-L1 axis in pre-clinical tumor models. This work provides important insights with respect to the further clinical development of checkpoint inhibitors.
authors.affiliation: Division of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. Electronic address: r.offringa@dkfz.de.
authors.forename: Rienk
authors.initials: R
authors.lastname: Offringa
authors.affiliation: Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Tremona Road, Southampton SO16 6YD, UK.
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Glennie
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology*; D060890:B7-H1 Antigen / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology*; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology*; D017452:Receptors, IgG / Q000276:immunology*
chemical_list: D000906:Antibodies; D060890:B7-H1 Antigen; D061026:Programmed Cell Death 1 Receptor; D017452:Receptors, IgG